Abbisko (2256) published its annual results for the year ended December 31, 2025. Revenue reached RMB612.12 million, rising from RMB503.99 million in 2024, indicating a 21% year-on-year increase. Research and development expenses were RMB508.44 million, up from RMB451.38 million a year earlier. The company’s reported profit stood at RMB55.25 million, compared with RMB28.30 million in 2024. Adjusted profit, excluding share-based payments, came in at RMB87.86 million, up from RMB49.04 million in the prior year.

As of December 31, 2025, Abbisko (2256) held RMB2.03 billion in cash and bank balances (including time deposits over three months and cash equivalents), compared with RMB1.96 billion at the end of 2024. The increase in cash was attributed to licensing-related revenue and higher interest-bearing bank borrowings.

The key product pipeline update for 2025 included the China approval of pimicotinib (ABSK021), an oral CSF-1R inhibitor, for Tenosynovial Giant Cell Tumor. Abbisko (2256) also secured acceptance of pimicotinib’s NDA filing by the US FDA in January 2026. In accompanying developments, the group advanced multiple other small-molecule oncology drug candidates, including irpagratinib (ABSK011) for hepatocellular carcinoma, ABSK043 (oral PD-L1) for non-small cell lung cancer combination trials, and ABSK061 (FGFR2/3) for gastric cancer/gastroesophageal junction cancer and achondroplasia.

Regarding corporate governance, the company announced the resignation of two joint company secretaries, effective March 2, 2026. One of them remains in other executive roles at Abbisko (2256). Two successors, Ms. Zhang and Ms. Lin, have been named new Joint Company Secretaries. Ms. Lin will also assume the positions of Authorised Representative and Process Agent.

No final dividend was declared for the reporting period.